IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study

被引：0

作者：

Shu, J. ^{[1
]}

Zhu, T. ^{[2
]}

Huang, Y. ^{[3
]}

Xu, Q. ^{[4
]}

Guo, R. ^{[5
]}

Liu, H. ^{[6
]}

Zhao, H. ^{[7
]}

Zhu, L. ^{[8
]}

Wang, X. ^{[9
]}

Xu, X. ^{[10
]}

Cheng, W. ^{[11
]}

Tang, J. ^{[12
]}

Zhu, Q. ^{[13
]}

Chen, X. ^{[14
]}

An, R. ^{[15
]}

Gao, J. ^{[16
]}

Li, G. ^{[17
]}

Zhang, Z. ^{[18
]}

Zhou, H. ^{[19
]}

Zhou, Q. ^{[20
]}

机构：

[1] Chongqing Univ, Affiliated Canc Hosp, Dept Gynecol, Chongqing, Peoples R China

[2] Zhejiang Canc Hosp, Gynaecol Oncol, Hangzhou, Peoples R China

[3] Hubei Canc Hosp, Gynecol Oncol, Wuhan, Peoples R China

[4] Fujian Prov Canc Hosp, Dept Gynecol Oncol, Fuzhou, Peoples R China

[5] Zhengzhou Univ, Affiliated Hosp 1, Gynaecol Oncol Dept, Zhengzhou, Peoples R China

[6] Gansu Prov Hosp, Gynecol Dept, Lanzhou, Peoples R China

[7] Shanxi Canc Hosp, Gynaecol Oncol Dept, Taiyuan, Peoples R China

[8] Nanjing Univ, Oncol Dept, Nanjing Drum Tower Hosp, Sch Med, Nanjing, Peoples R China

[9] Xuzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[10] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Gynecol Oncol, Beijing, Peoples R China

[11] Jiangsu Prov Hosp, Gynecol Dept, Nanjing, Peoples R China

[12] Hunan Canc Hosp, Gynecol Oncol, Changsha, Peoples R China

[13] Jiangxi Maternal & Child Hlth Care Hosp, Dept Oncol, Nanchang, Jiangxi, Peoples R China

[14] Fudan Univ, Dept Oncol, Jiangxi Maternal & Child Hlth Care Hosp, Shanghai, Peoples R China

[15] Xi An Jiao Tong Univ, Affiliated Hosp 1, Gynecol Dept, Xian, Peoples R China

[16] Jiangxi Canc Hosp, Dept Gynecol Oncol, Nanchang, Jiangxi, Peoples R China

[17] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gynecol & Oncol, Union, NJ USA

[18] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang, Peoples R China

[19] Innovent Biol Suzhou Co Ltd, Med Oncol, Suzhou, Peoples R China

[20] Chongqing Univ, Affiliated Canc Hosp, Gynecol Oncol, Chongqing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

720MO

引用

页码：S551 / S551

页数：1

共 50 条

[41] Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study
Yu, Xianjun
Zhang, Jian
Tazbirkova, Andrea
Yang, Jianwei
Yue, Jinbo
Sun, Yuping
Pan, Yueyin
Sun, Meili
Qin, Yanru
Shen, Lin
Song, Rongfeng
Ruan, Jian
Zhou, Aiping
Mou, Yiping
Liu, Zimin
Liu, Zhenyang
Zhang, Yongchang
Morris, Michelle
Aghmesheh, Morteza
Zhou, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Marathe, O.
Cheng, Y.
Spira, A. I.
Hamilton, E. P.
Rubinstein, M. M.
Dong, X.
Li, L.
Lv, D.
Shi, J.
Gabrail, N.
Amin, H.
Wu, C.
Zhu, Z.
Qiu, Y.
Gu, V.
Qiu, X.
Shi, R.
Liu, L.
Miao, P.
Ueno, N. T.
ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
[43] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC)
Peacock, N.
Saleh, M.
Bendell, J.
Rose, A. A.
Dong, Z.
Siegel, P. M.
Crowley, E.
Simantov, R.
Vahdat, L.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[44] 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.
Zhang, Jian
Liu, Rujiao
Gao, Shuiping
Yang, Huijuan
Chen, Jian
Yuan, Fang
Liu, Jiyan
Guo, Hongqian
Zhang, Shun
Li, XingYa
Yao, Xin
Bai, Ming
Bu, Hualei
Li, Yinyin
Hu, Changlu
Li, Xiumin
Wang, Zhen
Wang, ShanBing
Lou, Hanmei
Feng, Zhe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)
Beeram, M.
Krop, I.
Modi, S.
Tolcher, A.
Rabbee, N.
Girish, S.
Tibbitts, J.
Holden, S.
Lutzker, S.
Burris, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[46] ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+advanced breast cancer (ABC)
Hu, Xichun
Wang, Leiping
Zhang, Jian
Zhang, Qingyuan
Ouyang, Quchang
Wang, Xiaojia
Li, Wei
Xie, Weimin
Tong, Zhongsheng
Xu, Faliang
Liu, Wei
Wang, Shushen
Sun, Tao
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/ gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase study
Liu, J. J.
Yu, X.
Zhang, J.
Yang, J.
Yue, J.
Sun, Y.
Pan, Y.
Sun, M.
Qin, Y.
Shen, L.
Song, R.
Ruan, J.
Zhou, A.
Mou, Y.
Liu, Z.
Liu, Z.
Morris, M.
Aghmesheh, M.
Tazbirkova, A.
Zhou, H.
ANNALS OF ONCOLOGY, 2024, 35 : S160 - S160
[48] A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).
Burris, H.
Saleh, M.
Bendell, J.
Hart, L.
Rose, A. A. N.
Dong, Z.
Siegel, P. M.
Crane, M. F.
Donovan, D.
Crowley, E.
Simantov, R.
Vahdat, L.
CANCER RESEARCH, 2009, 69 (24) : 855S - 855S
[49] Phase I, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic or biliary cancers.
Ko, Andrew H.
Coveler, Andrew L.
Schlechter, Benjamin L.
Bekaii-Saab, Tanios S.
Wolpin, Brian M.
Clark, Jeffrey William
Bockorny, Bruno
Bai, Li-Yuan
Cheng, Yi-Lin
Cheng, Ting-Ying
Langecker, Peter J.
Lin, Shih-Yao
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] A phase I study of BAT1006, a novel anti-HER2 antibody, in patients with locally advanced/metastatic solid tumors
Mei, Xingxing
Tang, Weijia
Song, Shuqiang
Wang, Hao
Cao, Chuanqi
Feng, Cuiying
Thomas, Bert E.
Li, Shengfeng
Yu, Jin-Chen
CANCER RESEARCH, 2023, 83 (08)

← 1 2 3 4 5 →